← All trials
NCT05335109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Nov 8, 2024
- Completion date
- Nov 29, 2024
- First posted
- Apr 19, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Negovsky Reanimatology Research InstituteLead sponsor
- Negovsky Reanimatology Research InstituteReponsible party - principal investigator
- Negovsky Reanimatology Research InstituteSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.